Home Page
03:59:28 EDT Wed 22 Oct 2014
Enter Symbol
or Name
USA
CA



TRINITY BIOTECH PLC ADS
Symbol U : TRIB
Recent Sedar Documents

Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2012 Financial Results

2013-02-20 11:01 ET - News Release

DUBLIN, Ireland, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, March 5, 2013. The Company has scheduled a conference call for that same day, Tuesday, March 5, 2013 at 11:00am EST (4:00pm GMT) to discuss the results of the quarter.

Interested parties can access the call by dialing:
USA: 1-877-317-6789
International: 1-412-317-6789
Conference ID #: 10025641
   
A simultaneous webcast of the call can be accessed at: 
http://www.videonewswire.com/event.asp?id=92502
   
A replay of the call can be accessed until March 12, 2013 by dialing:
   
USA: 1-877-344-7529
International: 1-412-317-0088
Conference ID #: 10025641
   
The webcast of the call will be available for 30 days at: 
http://www.videonewswire.com/event.asp?id=92502

About Trinity Biotech plc

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

The Trinity Biotech plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10602

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

CONTACT: Trinity Biotech plc
         Kevin Tansley
         (353)-1-2769800
         E-mail: kevin.tansley@trinitybiotech.com
         
         Lytham Partners LLC
         Joe Diaz, Joe Dorame & Robert Blum
         602-889-9700

© 2014 Canjex Publishing Ltd. All rights reserved.